Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-r6qrq Total loading time: 0 Render date: 2024-04-26T21:13:22.423Z Has data issue: false hasContentIssue false

2 - Cognitive disorders in people living with HIV disease

Published online by Cambridge University Press:  06 August 2009

By
Julie D. Maggi M.D., M.sc. ,
Sean B. Rourke Ph.D.  and
Mark Halman M.D.
Edited by
Kenneth Citron ,
Marie Josée Brouillette  and
Alexandra Beckett
Julie D. Maggi M.D., M.sc.
Affiliation:
Assistant Professor of Psychiatry, University of Toronto, Staff Psychiatrist, Mental Health Services, St. Michael's Hospital, Toronto, Canada
Sean B. Rourke Ph.D.
Affiliation:
Associate Professor of Psychiatry, University of Toronto, Director of Research, Mental Health Services, St. Michael's Hospital, Toronto, Canada
Mark Halman M.D.
Affiliation:
Assistant Professor of Psychiatry, University of Toronto, Director, HIV Psychiatry Program, St. Michael's Hospital, Toronto, Canada
Marie Josée Brouillette
Affiliation:
McGill University, Montréal
Alexandra Beckett
Affiliation:
Harvard University, Massachusetts
Get access

Summary

Introduction

Cognitive complaints are common in HIV disease. Over the course of the HIV epidemic, researchers have come to understand a great deal about cognitive difficulties associated with HIV disease. HIV enters the central nervous system shortly after infection and has a predilection for subcortical brain areas. As the disease progresses, proinflammatory neurotoxins that cause cell injury and cell dysfunction are released. As a result, many people with HIV disease begin to experience difficulties in cognitive functioning. Given the morbidity associated with cognitive disorders for people living with HIV disease, it is essential that practitioners accurately assess changes in mental status. Diagnosis must be grounded in a thorough history and careful psychiatric, mental status, neurologic examination, and where available, neuropsychological examination. Assessment must consider the patient's clinical stage as well as laboratory markers of immune dysfunction and viral burden.

What causes the cognitive dysfunction associated with HIV infection?

The pathophysiologic mechanism that leads to cognitive dysfunction is unclear, but is thought to be related to HIV replication in the brain, activation of HIV-infected brain microglial cells, liberation of inflammatory neurotoxins (e.g., cytokines, Tumour Necrosis Factor), and impairment in natural host repair mechanisms, ultimately resulting in a level of neuronal dysfunction, injury, or death. The areas most affected are the subcortical brain regions and the fronto-striatal circuitry (Cummings, 1990; Parks et al., 1993; Wesselingh et al., 1994; Tyor et al., 1995; Grant and Adams, 1996; Masliah et al., 1997; Tan and Guiloff, 1998).

Type
Chapter
Information
HIV and Psychiatry
Training and Resource Manual
 , pp. 30 - 55
Publisher: Cambridge University Press
Print publication year: 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Albert, S. M., Marder, K., Dooneief, G.et al. Neuropsychologic impairment in early HIV infection: A risk factor for work disability. Archives of Neurology, 52(5) (1995): 525–30.Google Scholar
Albert, S. M., Weber, C., Todak, G.et al. An observed performance test of medication management ability in HIV: relation to neuropsychological status and medication adherence outcomes. Aids and Behavior, 3(2)(1999): 121–8.Google Scholar
American Academy of Neurology AIDS Task Force. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus type-1 (HIV-1) infection. Neurology, 41(6)(1991): 778–85.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder. 4thedn text revised. Washington, DC: American Psychiatric Association, 2000.
Aweeka, F., Jayewardene, A., Staprans, S.et al. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology, 20 (1999): 39–43.Google Scholar
Breitbart, W., Rosenfeld, B., Kaim, M. and Funesti-Esch, J.A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Archives of Internal Medicine, 161(3)(2001): 411–20.Google Scholar
Brew, B. J., Brown, S. J., Catalan, J. et al., Safety and efficacy of abacavir (ABC, 1592) in AIDS dementia complex (study CNAB 3001) (abstract no. 32192). 12th World AIDS Conference, Geneva, Switzerland, 1998.
Catz, S. L., Kelly, J. A., Bogart, L. M.et al. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatment for HIV disease. Health Psychology, 19(2) (2000): 124–133.Google Scholar
Chang, L., Ernst, T., Leonido-Yee, M.et al. Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology, 52(1) (1999): 100–8.Google Scholar
Cohen, R. A., Boland, R., Paul, R.et al. Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. AIDS, 15(3) (2001): 341–5.Google Scholar
Cummings, J. L.Subcortical Dementia. New York: Oxford University Press, 1990.
Dore, G. J., Correll, P. K., Li, Y.et al. Changes in AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS, 13(1999): 1249–53.Google Scholar
Ellis, R. J., Deutsch, R., Heaton, R. K.et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. Archives of Neurology, 54(1997): 416–24.Google Scholar
Ellis, R. J., Moore, D. J., Childers, M. E.et al. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Archives of Neurology, 59(6) (2002): 923–8.Google Scholar
Ferrando, S., Gorp, W., McElhiney, M.et al. Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS, 12(8) (1998): F65–70.Google Scholar
Filippi, C. G., Sze, G., Farber, S. J.et al. Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy. Radiology, 206(1998): 491–8.Google Scholar
Galgani, S., Balestra, P., Tozzi, V.et al. Comparison of efficacy of different antiretroviral regimens on neuropsychological performance in HIV-1 patients (abstract). Journal of NeuroVirology, 4(1998): 350.Google Scholar
Grant, I. and Adams, K. M. (eds.) Neuropsychological Assessment of Neuropsychiatric Disorders. New York: Oxford University Press, 1996.
Grant, I. and Martin, A.Neuropsychology of HIV infection. New York: Oxford University Press, 1994.
Heaton, R. K., and Grant, I. Neurobehavioral Progress Report/Preliminary Studies (research plan present to NIMH, Office on AIDS), Grant, I., ed. San Diego, CA: HIV Neurobehavioral Research Center, 1995.
Heaton, R. K., Marcotte, T. D., White, D. A.et al. Nature and vocational significance or neuropsychological impairment associated with HIV infection. Clinical Neuropsychologist, 10 (1996): 1–14.Google Scholar
Heaton, R. K., Velin, R. A., McCutchan, J. A.et al. Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. HNRC Group, HIV Neurobehavioral Research Center. Psychosomatic Medicine, 56(1)(1994): 8–17.Google Scholar
Hriso, E., Kuhn, T., Masdeu, J. C. and Grundman, M.Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. American Journal of Psychiatry, 148(11)(1991): 1558–61.Google Scholar
Kaplan, R. M., Anderson, J. P., Patterson, T. L.et al. Validity of the quality of well-being scale for persons with human immunodeficiency virus infection. HNRC Group, HIV Neurobehavioral Research Center. Psychosomatic Medicine, 57(2) (1995): 138–47.Google Scholar
Letendre, S., Ellis, R., Heaton, R. K.et al. Change in CSF RNA level correlates with the effects of antiretroviral therapy on HIV-1 associated neurocognitive disorder (abstract no. 32198). Journal of NeuroVirology, 4(1998): 357.Google Scholar
Maggi, J. D. and Halman, M. H.The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with manic syndromes. Canadian Journal of Psychiatry, 46(4) (2001): 359–62.Google Scholar
Marder, K., Albert, S. M., McDermott, M. and the DANA Consortium on therapy for HIV dementia and related disorders. Prospective study of neurocognitive impairment in HIV (DANA cohort): dementia and mortality outcomes. Journal of NeuroVirology, 4 (1998): 358.Google Scholar
Martin, E. M., Pitrak, D. L., Pursell, K. J.et al. Information processing and antiretroviral therapy in HIV-1 infection. Journal of the International Neuropsychological Society, 4(1998): 329–35.Google Scholar
Masliah, E., Heaton, R. K., Marcotte, T. D.et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. Annals of Neurology, 42(1997): 963–72.Google Scholar
McArthur, J. C., Hoover, D. R., Bacellar, H.et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology, 43(11) (1993): 2245–52.Google Scholar
McArthur, J. C., McClernon, D. R., Cronin, M. F.et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Annals of Neurology, 42(5) (1997): 689–98Google Scholar
Moog, C., Kuntz-Simon, G., Caussin-Schwemling, C. and Obert, G.Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels. Journal of General Virology, 77(1996): 1993–9.Google Scholar
Neuenburg, J. K., Brodt, H. R., Herndier, B. G.et al. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 31(2) (2002): 171–7.Google Scholar
Parks, R. W., Zec, R. F. and Wilson, R. S. (eds.). Neuropsychology of Alzheimer's Disease and Other Dementias. New York: Oxford University Press, 1993.
Paterson, D. L., Swindells, S., Mohr, J. and Brester, M.Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133(1) (2000): 21–30.Google Scholar
Power, C., Selnes, O. A., Grim, J. A., and McArthur, J. C.HIV Dementia Scale: a rapid screening test. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology, 8(3) (1995): 273–8.Google Scholar
Price, R. W. and Brew, B. J.The AIDS dementia complex. Journal of Infectious Diseases, 158(1992): 1079–83.Google Scholar
Rourke, S. B., Bassel, C. and Halman, M. H.Neurocognitive complaints in HIV-infection and their relationship to depressive symptoms and neuropsychological functioning. Journal of Clinical and Experimental Neuropsychology, 21 (1999a): 737–56.Google Scholar
Rourke, S. B., Bassel, C. and Halman, M. H.Neuropsychiatric correlates of memory-metamemory dissociations in HIV-1 infection. Journal of Clinical and Experimental Neuropsychology, 21(1999b): 757–68.Google Scholar
Sacktor, N. C., Lyles, R. H., Skolasky, R. L.et al. Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS). Neurology, 52(8) (1999): 1640–7.Google Scholar
Schmitt, F. A., Bigley, J. W., McKinnis, R.et al. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine, 319(24) (1988): 1573–8.Google Scholar
Sidtis, J. J., Gatsonis, C., Price, R. W.et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Annals of Neurology, 33(4)(1993): 343–9.Google Scholar
Simon, G., Moog, C. and Obert, G.. Valproic acid reduces the intracellular level of glutathione and stimulates human immunodeficiency virus. Chemico-Biological Interactions, 91 (1994): 111–21.Google Scholar
Smith, C. A., Gorp, W. G., Ryan, E. R.et al. (2003). Screening subtle HIV-related cognitive dysfunction: the clinical utility of the HIV Dementia Scale. Journal of AIDS, 33(1) (2003): 116–18.Google Scholar
Stankoff, B., Calves, V., Suarez, S.et al. Plasma and cerebrospinal fluid human immunodeficiency virus type-1 (HIV-1) RNA levels in HIV-related cognitive impairment. European Journal of Neurology, 6(6) (1999): 669–75.Google Scholar
Tan, S. V. and Guiloff, R. J.Hypothesis on the pathogenesis of vacuolar myelopathy, dementia, and peripheral neuropathy in AIDS [comment]. Journal of Neurology, Neurosurgery and Psychiatry, 65(1) (1998): 23–8.Google Scholar
Tozzi, V., Balestra, P., Galgani, S.et al. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS, 13(14) (1999): 1889–97.Google Scholar
Tyor, W. R., Wesselingh, S. L., Griffin, J. W.et al. Unifying hypothesis for the pathogenesis of HIV-associated dementia complex, vacuolar myelopathy, and sensory neuropathy. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology, 9(1995): 379–88.Google Scholar
Wesselingh, S. L., Glass, J., McArthur, J. C.et al. Cytokine dysregulation in HIV-associated neurological disease. Advances in Neuroimmunology, 4(3) (1994): 199–206.Google Scholar
White, J. L., Darko, D. F., Brown, S. J.et al. Early central nervous system response to HIV infection: sleep distortion and cognitive-motor decrements. AIDS, 9(9) (1995): 1043–50.Google Scholar
Witvrouw, M., Schmit, J. C., Remoortel, B.et al. Cell type-dependent effect of sodium valproate on human immunodeficiency virus type 1 replication in vitro. AIDS Research and Human Retroviruses, 13 (1997): 187–92.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×